Amyloid fibril formation by human stefin B: influence of pH and TFE on fibril growth and morphology

References

• Turk V, Bode W. The cystatins; protein inhibitors of cysteine proteinases. FEBS Lett 1991; 285: 213–219
   PubMed Web of Science ®Google Scholar
• Turk B, Turk D, Salvesen G S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des 2002; 8: 1623–1637
   PubMed Web of Science ®Google Scholar
• Jones B, Roberts P J, Faubion W A, Kominami E, Gores G J. Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Am J Physiol 1998; 275: G723–G723
   PubMed Web of Science ®Google Scholar
• Pennacchio L A, Bouley D M, Higgins K M, Scott M P, Noebels J L, Myers R M. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nature Genet 1998; 20: 251–258
   PubMed Web of Science ®Google Scholar
• Lieuallen K, Pennacchio L A, Park M, Myers R M, Lennon G G. Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes. Hum Mol Genet 2001; 10: 1867–1871
   PubMed Web of Science ®Google Scholar
• Pennacchio L A, Lehesjoki A E, Stone N E, Willour V L, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskiniemi M, Warrington J A, Norio R, de la Chapelle A, Cox D R, Myers R M. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271: 1731–1734
   PubMed Web of Science ®Google Scholar
• Bespalova I N, Adkins S, Pranzatelli M, Burmeister M. Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient. Am J Med Genet 1997; 74: 467–471
   PubMed Web of Science ®Google Scholar
• Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S. Unverricht-Lundborg disease with cystatin B gene abnormalities. Pediatr Neurol 2002; 26: 55–60
   PubMed Web of Science ®Google Scholar
• Jensson O, Palsdottir A, Thorsteinsson L, Arnason A, Abrahamson M, Olafsson I, Grubb A. Cystatin C mutation causing amyloid angiopathy and brain hemorrhage. Biol Chem Hoppe Seyler 1990; 371(Suppl.)229–232
   PubMed Web of Science ®Google Scholar
• Bjarnadottir M, Nilsson C, Lindström V, Westman A, Davidsson P, Thormodsson F, Blöndal H, Gudmundsson G, Grubb A. The cerebral hemorrhage-producing cystatin C variant (L68Q) in extracellular fluids. Amyloid: J Protein Folding Disord 2001; 8: 1–10
   PubMed Web of Science ®Google Scholar
• Deng A, Irizarry M C, Nitsch R M, Growdon J H, Rebeck G W. Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am J Pathol 2001; 159: 1061–1068
   PubMed Web of Science ®Google Scholar
• Ii K, Ito H, Kominami E, Hirano A. Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch A Pathol Anat Histopathol 1993; 423: 185–194
   PubMedGoogle Scholar
• Žerovnik E, Pompe-Novak M, Škarabot M, Ravnikar M, Muševič I, Turk V. Human stefin B readily forms amyloid fibrils in vitro. Biochim Biophys Acta 2002; 1594: 1–5
   PubMedGoogle Scholar
• Jenko S, Škarabot M, Kenig M, Gunčar G, Muševič I, Turk D, Žerovnik E. Different propensity to form amyloid fibrils by two homologous proteins – human stefins A and B: searching for an explanation. Proteins 2004; 55: 417–425
   PubMed Web of Science ®Google Scholar
• Žerovnik E, Zavašnik-Bergant V, Kopitar-Jerala N, Pompe-Novak M, Škarabot M, Goldie K, Ravnikar M, Muševič I, Turk V. Amyloid fibril formation by human stefin B in vitro: immunogold labelling and comparison to stefin A. Biol Chem 2002; 383: 859–863
   PubMed Web of Science ®Google Scholar
• Anderluh G, Gutierrez-Aguirre I, Rabzelj S, Čeru S, Kopitar-Jerala N, Maček P, Turk V, Žerovnik E. Interaction of human stefin B in the prefibrillar oligomeric form with membranes – correlation with cellular toxicity. FEBS J 2005; 272: 3042–3051
   PubMed Web of Science ®Google Scholar
• Jerala R, Žerovnik E. Accessing the global minimum conformation of stefin A dimer by annealing under partially denaturing conditions. J Mol Biol 1999; 291: 1079–1089
   PubMed Web of Science ®Google Scholar
• Konno T, Murata K, Nagayama K. Amyloid-like aggregates of a plant protein: a case of a sweet-tasting protein, monellin. FEBS Letts 1999; 454: 122–126
   PubMed Web of Science ®Google Scholar
• Kenig M, Jenko-Kokalj S, Tušek-Žnidarič M, Pompe-Novak M, Gunčar G, Turk D, Waltho J P, Staniforth R A, Avbelj F, Žerovnik E. Folding and amyloid fibril formation for a series of human stefins' chimeras: any correlation?. Proteins 2006; 62: 918–927
   PubMed Web of Science ®Google Scholar
• Nillson M, Wang X, Rodziewicz-Motowidlo S, Janowski R, Lindström V, Önnerfjord P, Westermark G, Grzonka Z, Jaskolski M, Grubb A. Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C. J Biol Chem 2004; 279: 24236–24245
   PubMed Web of Science ®Google Scholar
• Lomakin A, Teplow D B, Kirschner D A, Benedek G B. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci USA 1997; 94: 7942–7947
   PubMed Web of Science ®Google Scholar
• Munishkina L A, Phelan C, Uversky V N, Fink A L. Conformational behavior and aggregation of α-synuclein in organic solvents: modeling the effects of membranes. Biochemistry 2003; 42: 2720–2730
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Žerovnik E, Yamada T, Turk V. Conformational changes preceding amyloid fibril formation of amyloid-beta and stefin B; parallels in pH dependence. Curr Med Chem 2002; 9: 1717–1724
   PubMed Web of Science ®Google Scholar
• Matsunaga Y, Žerovnik E, Yamada T, Turk V. Conformational changes preceding amyloid fibril formation of amyloid-beta, prion protein and stefin B; parallels in pH dependence. Med Chem Rev Online 2005; 2: 359–367
   Google Scholar
• Jerala R, Trstenjak M, Lenarčič B, Turk V. Cloning a synthetic gene for human stefin B and its expression in E. coli. FEBS Lett 1988; 239: 41–44
   PubMed Web of Science ®Google Scholar
• Craig W S. Determination of quaternary structure of an active enzyme using chemical cross-linking with glutaraldehyde. Methods Enzymol 1988; 156: 333–345
   PubMed Web of Science ®Google Scholar
• Wall J, Solomon A. Flow cytometric characterization of amyloid fibrils. Methods Enzymol 1999; 309: 460–466
   PubMed Web of Science ®Google Scholar
• Žerovnik E, Turk V, Waltho J P. Amyloid fibril formation by human stefin B: influence of the initial pH-induced intermediate state. Biochem Soc Trans 2002; 30: 543–547
   PubMed Web of Science ®Google Scholar
• Žerovnik E, Jerala R, Kroon-Žitko L, Turk V, Lohner K. Characterization of the equilibrium intermediates in acid denaturation of human stefin B. Eur J Biochem 1997; 245: 364–372
   PubMedGoogle Scholar
• Žerovnik E, Giannini S, Stoka V, Tušek-Žnidarič M, Pompe-Novak M, Staniforth R A. The mechanism of amyloid fibrillation: stefin B as a good model protein. The molecular anatomy and physiology of proteins: human stefins and cystatins, E Žerovnik, N Kopitar-Jerala, V U Uversky. Nova Science, New York 2006; 97–114
   Google Scholar
• Smith D P, Jones S, Serpell L C, Sunde M, Radford S E. A systematic investigation into the effect of protein destabilisation on beta 2-microglobulin amyloid formation. J Mol Biol 2003; 330: 943–954
   PubMed Web of Science ®Google Scholar
• Žerovnik E, Virden R, Jerala R, Kroon-Žitko L, Turk V, Waltho J P. Differences in the Effects of TFE on the folding pathways of human stefins A and B. Proteins 1999; 36: 205–216
   PubMed Web of Science ®Google Scholar
• Žerovnik E, Kenig M, Waltho J P, Staniforth R A. Conclusions on the mechanism of protein folding from stefins and cystatins studies. The molecular anatomy and physiology of proteins: human stefins and cystatins, V U Uversky, E Žerovnik, N Kopitar-Jerala. Nova Science, New York 2006; 61–74
   Google Scholar
• Klunk W E, Jacob R F, Mason R P. Quantifying amyloid by congo red spectral shift assay. Methods Enzymol 1999; 309: 285–305
   PubMed Web of Science ®Google Scholar
• Hamada D, Goto Y. The equilibrium intermediate of β-lactoglobulin with non-native α-helical structure. J Mol Biol 1997; 269: 479–487
   PubMed Web of Science ®Google Scholar
• Fezoui Y, Teplow D B. Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J Biol Chem 2002; 277: 36948–36954
   PubMed Web of Science ®Google Scholar
• Chiti F, Taddei N, Bucciantini M, White P, Ramponi G, Dobson C M. Mutational analysis of the propensity for amyloid formation by a globular protein. EMBO J 2000; 19: 1441–1449
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Naiki H, Goto Y. Mechanism by which the amyloid-like fibrils of β2-microglobulin fragment are induced by fluorine-substituted alcohols. J Mol Biol 2006; 363: 279–288
   PubMed Web of Science ®Google Scholar
• Grudzielanek S, Jansen R, Winter R. Solvational tuning of the unfolding, aggregation and amyloidogenesis of insulin. J Mol Biol 2006; 351: 879–894
   Web of Science ®Google Scholar
• Rabzelj S, Turk V, Žerovnik E. In vitro study of stability and amyloid fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1. Protein Sci 2005; 14: 2713–2722
   PubMed Web of Science ®Google Scholar
• Kad N M, Myers S L, Smith D P, Smith D A, Radford S E, Thomson N H. Hierarchical assembly of β2-microglobulin amyloid in vitro revealed by atomic force microscopy. J Mol Biol 2003; 330: 785–797
   PubMed Web of Science ®Google Scholar
• Gosal W S, Morten I J, Hewitt E W, Smith D A, Thomson N H, Radford S E. Competing pathways determine fibril morphology in the self-assembly of beta2-microglobulin into amyloid. J Mol Biol 2005; 351: 850–864
   PubMed Web of Science ®Google Scholar
• Kirkitadze M D, Condron M M, Teplow D B. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol 2001; 312: 1103–1119
   PubMed Web of Science ®Google Scholar
• Souillac P O, Uversky V N, Fink A L. Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN. Biochemistry 2003; 42: 8094–8104
   PubMed Web of Science ®Google Scholar
• Kad N M, Thomson N H, Smith D P, Smith D A, Radford S E. β2-Microglobulin and its deamidated variant, N17D, form amyloid fibrils with a range of morphologies in vitro. J Mol Biol 2001; 313: 559–571
   PubMed Web of Science ®Google Scholar
• Malisauskas M, Zamotin V, Jass J, Noppe W, Dobson C M, Morozova-Roche L A. Amyloid protofilaments from the calcium-binding protein equine lysozyme: formation of ring and linear structures depends on pH and metal ion concentration. J Mol Biol 2003; 330: 879–890
   PubMed Web of Science ®Google Scholar
• Žerovnik E. Amyloid fibril formation; proposed mechanisms and relevance to conformational disease. Eur J Biochem 2002; 269: 3362–3371
   PubMedGoogle Scholar
• Lomakin A, Teplow D B, Kirschner D A, Benedek G B. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci U S A 1997; 94: 7942–7947
   PubMed Web of Science ®Google Scholar
• Yong W, Lomakin A, Kirkitadze M D, Teplow D B, Chen S H, Benedek G B. Structure determination of micelle-like intermediates in amyloid beta-protein fibril assembly by using small angle neutron scattering. Proc Natl Acad Sci USA 2002; 99: 150–154
   PubMed Web of Science ®Google Scholar
• Tjernberg L O, Pramanik A, Bjorling S, Thyberg P, Thyberg J, Nordstedt C, Berndt K D, Terenius L, Rigler R. Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy. Chem Biol 1999; 6: 53–62
   PubMed Web of Science ®Google Scholar
• Serag A A, Altenbach C, Gingery M, Hubbell W L, Yeates T O. Identification of a subunit interface in transthyretin amyloid fibrils: evidence for self-assembly from oligomeric building blocks. Biochemistry 2001; 40: 9089–9096
   PubMed Web of Science ®Google Scholar
• Chamberlain A K, MacPhee C E, Zurdo J, Morozova-Roche L A, Hill H A, Dobson C M, Davis J J. Ultrastructural organization of amyloid fibrils by atomic force microscopy. Biophys J 2000; 79: 3282–3293
   PubMed Web of Science ®Google Scholar
• Lambert M P, Barlow A K, Chromy B A, Edwards C, Freed R, Liosatos M, Morgan T E, Rozovsky I, Trommer B, Viola K L, Wals P, Zhang C, Finch C E, Krafft G A, Klein W L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95: 6448–6553
   PubMed Web of Science ®Google Scholar
• Lashuel H A, Hartley D, Petre B M, Walz T, Lansbury P T, Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002; 418: 291
   PubMed Web of Science ®Google Scholar
• Walsh D M, Hartley D M, Kusumoto Y, Fezoui Y, Condron M M, Lomakin A, Benedek G B, Selkoe D J, Teplow D B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999; 274: 25945–25952
   PubMed Web of Science ®Google Scholar
• Janowski R, Kozak M, Jankowska E, Grzonka Z, Grubb A, Abrahamson A, Jaskolski M. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat Struct Biol 2001; 8: 316–320
   PubMedGoogle Scholar
• Staniforth R A, Giannini S, Higgins L D, Conroy M J, Hounslow A M, Jerala R, Craven C J, Waltho J P. Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily. EMBO J 2001; 20: 4774–4781
   PubMed Web of Science ®Google Scholar
• Sanders A, Jeremy Craven C, Higgins L D, Giannini S, Conroy M J, Hounslow A M, Waltho J P, Staniforth R A. Cystatin forms a tetramer through structural rearrangement of domain-swapped dimers prior to amyloidogenesis. J Mol Biol 2004; 336: 165–178
   PubMed Web of Science ®Google Scholar
• Jenko Kokalj S, Gunčar G, Štern I, Morgan G, Rabzelj S, Kenig M, Staniforth R A, Waltho J P, Žerovnik E, Turk D. Essential role of proline isomerization in stefin B tetramer formation. J Mol Biol 2007; 366: 1569–1579
   PubMed Web of Science ®Google Scholar